Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression

Experimental Hematology

Volumn 42, Issue 2, 2014, Pages 90-100

  Herrmann, Markus D ^a,c   Lennerz, Jochen K ^a   Bullinger, Lars ^a   Bartholomae, Stephan ^a   Holzmann, Karlheinz ^a   Westhoff, Mike Andrew ^a   Corbacioglu, Selim ^b   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RESISTANCE; CELL CLONE; CELL LINE; CELL MUTANT; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HUMAN CELL; KASUMI 1; LEUKEMIA CELL; LONG TERM EXPOSURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THIAZOLES; TRANSLOCATION, GENETIC;

EID: 84896692294     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.10.006     Document Type: Article

References (42)

1. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
2. Rosenzweig S.A. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 2012, 83:1041-1048.
3. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008, 18:73-79.
4. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
5. Koppikar P., Bhagwat N., Kilpivaara O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
6. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
7. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
8. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
9. Wilson T.R., Fridlyand J., Yan Y., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
10. Bernards R. A missing link in genotype-directed cancer therapy. Cell 2012, 151:465-468.
11. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
12. Sharma S.V., Haber D.A., Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010, 10:241-253.
13. Malaise M., Steinbach D., Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 2009, 4:77-82.
14. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
15. Reikvam H., Hatfield K.J., Kittang A.O., Hovland R., Bruserud O. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol 2011, 2011:104631.
16. Muller A.M., Duque J., Shizuru J.A., Lubbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 2008, 27:5759-5773.
17. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1198-1206.
18. Pappa V., Kontsioti F., Liakata E., et al. Dasatinib is an effective inhibitor of proliferation and inducer of apoptosis in the KASUMI cell line bearing the T(8;21)(q22;q22) and the N822K KIT Mutation. ASH Annual Meeting Abstracts 2008, 112:5054.
19. Wang Y.Y., Zhao L.J., Wu C.F., et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A 2011, 108:2450-2455.
20. Fischer T., Stone R.M., Deangelo D.J., et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010, 28:4339-4345.
21. Boissel N., Jourdan E., Pigneux A., et al. Single-agent dasatinib does not prevent hematological relapse in patients with core binding factor (CBF) acute myeloid leukemia (AML) in first complete remission, but persistent or re-appearing molecular minimal residual disease-results of the DASA-CBF Trial From the French AML Intergroup. ASH Annual Meeting Abstracts 2011, 118:2608.
22. Sierra J.R., Cepero V., Giordano S. Molecular mechanisms of acquiredresistance to tyrosine kinase targeted therapy. Mol Cancer 2010, 9:75.
23. Diamond J.M., Melo J.V. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011, 52(Suppl 1):12-22.
24. Tang C., Schafranek L., Watkins D.B., et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma 2011, 52:2139-2147.
25. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
26. Han L., Schuringa J.J., Mulder A., Vellenga E. Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases. Ann Hematol 2010, 89:861-871.
27. Guerrouahen B.S., Futami M., Vaklavas C., et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010, 16:1149-1158.
28. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108:3504-3513.
29. Fulda S., Strauss G., Meyer E., Debatin K.M. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000, 95:301-308.
30. Irizarry R.A., Hobbs B., Collin F., et al. Exploration, normalization, and summaries of high-density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
31. Bullinger L., Rucker F.G., Kurz S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007, 110:1291-1300.
32. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
33. Shah N.P., Kasap C., Weier C., et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008, 14:485-493.
34. Sharma S.V., Lee D.Y., Li B., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
35. Ashman L.K., Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig 2013, 22:103-115. http://www.ncbi.nlm.nih.gov/pubmed?term=Griffith%20R%5BAuthor%5D%26cauthor=true%26cauthor_uid=23127174Drugs.
36. Zhou J., Bi C., Janakakumara J.V., et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009, 113:4052-4062.
37. Stolzel F., Steudel C., Oelschlagel U., et al. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann Hematol 2010, 89:653-662.
38. Baylin S.B. Resistance, epigenetics and the cancer ecosystem. Nat Med 2011, 17:288-289.
39. McDermott U., Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009, 27:5650-5659.
40. Pierotti M.A., Tamborini E., Negri T., Pricl S., Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011, 8:161-170.
41. Weisberg E., Ray A., Nelson E., et al. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 2011, 6:e25351.
42. Lamb J., Crawford E.D., Peck D., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.